MicroRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.

ABSTRACT:

Background

Gastrointestinal stromal tumour (GIST) is mainly initialised by receptor tyrosine kinase gene mutations. Although the tyrosine kinase inhibitor imatinib mesylate considerably improved the outcome of patients, imatinib resistance still remains a major therapeutic challenge in GIST therapy. Herein we evaluated the clinical impact of microRNAs in imatinib-treated GISTs.

Methods

The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples.

Results

We showed that overexpression levels of miR-125a-5p and miR-107 were associated with im

SUBMITTER: Akcakaya P 

PROVIDER: S-EPMC4260040 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature